Phase 2 × Burkitt Lymphoma × fludarabine phosphate × Clear all
NCT04191187 2025-12-11

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
34 enrolled 14 charts
NCT03779854 2025-10-15

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Recruiting
68 enrolled
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT01028716 2023-01-23

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 2 Terminated
46 enrolled 18 charts
NCT00309842 2020-09-10

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
213 enrolled 19 charts
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT00119392 2018-06-29

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
42 enrolled 11 charts
NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts
NCT01427881 2017-05-19

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
43 enrolled 14 charts
NCT00049504 2017-05-17

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT01652014 2016-07-14

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
NCT00053196 2016-07-01

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
82 enrolled
NCT00134004 2015-10-06

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
210 enrolled 10 charts
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00004145 2014-03-07

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Chicago

Phase 2 Completed
16 enrolled
NCT00084695 2014-01-10

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts
NCT00006379 2011-12-08

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Case Comprehensive Cancer Center

Phase 2 Completed
58 enrolled
NCT00806767 2011-05-17

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
82 enrolled
NCT00055653 2011-03-07

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Roswell Park Cancer Institute

Phase 2 Completed
NCT00740467 2010-01-28

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled